AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 302 min read$CAPR

Bergmann Anthony sold $732K of CAPR

Bergmann Anthony (CHIEF FINANCIAL OFFICER) sold 24,100 shares of CAPRICOR THERAPEUTICS, INC. (CAPR) at $30.38 ($0.73M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bergmann Anthony
Published Jun 30, 2026, 1:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 1:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CAPR
Neutral
high confidence
Mentioned
$CAPR
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAPRNeutralLow
01

Why it matters

The CFO’s open-market sale (24,100 shares at $30.38) is disclosed as part of a pre-arranged 10b5-1 plan, suggesting limited informational content beyond routine compliance.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not introduce new fundamentals.

03

What to watch

Insider sales can still matter if they cluster or if future filings show continued selling without offsetting buys; this article provides only one transaction snapshot.

Relevance 4/10Novelty 5/10Timing: SEC Form 4 filed late June; reflects sale executed 2026-06-25.

Background

The article summarizes an SEC Form 4 insider transaction for Capricor Therapeutics, Inc. (CAPR).

Company-level read

Ticker impact

$CAPRNeutralHigh confidence
Context

Capricor Therapeutics CFO Bergmann Anthony sold 24,100 shares in an open-market transaction for about $732K, per SEC Form 4.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact would be short-lived sentiment noise.

Evidence & confidence

The filing is a Form 4 insider sale by the CFO, explicitly under a pre-arranged Rule 10b5-1 plan, with no accompanying new operational or financial guidance in the text.

Market effects

Sector

Minimal; this is company-specific insider transaction with no sector-wide regulatory/clinical catalyst mentioned.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may be mechanically scheduled and not a bearish signal; traders may discount it entirely.

Key entities

  • issuer
    CAPRICOR THERAPEUTICS, INC.

    Subject of the Form 4 insider transaction; CFO sale disclosed.

  • insider
    Bergmann Anthony

    Chief Financial Officer who sold shares.

  • trading mechanism
    Rule 10b5-1 plan

    Pre-arranged plan noted as Yes in the filing.

Read at source← All news

Related articles

AUG 7
$CAPRMedAI 8/10

Why did CAPR, LKQ, PSKY Stocks Plunge To 52-Week Lows Today?

Capricor Therapeutics (CAPR) fell 36% to a 52-week low after an FDA advisory committee voted 9-3 against recommending Deramiocel approval, citing clinical evidence concerns. JonesResearch downgraded CAPR to Hold. LKQ dropped 14% to a six-year low after Q2 revenue and EPS missed estimates and guidance was cut. Paramount Skydance (PSKY) slid 2% on ongoing legal issues around its Warner Bros. Discovery deal.

stocktwits.com4 min
JUL 30
$CAPRMedAI 8/10

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

Capricor Therapeutics (NASDAQ: CAPR) said the FDA Cellular, Tissue and Gene Therapies Advisory Committee voted 3-9 (0 abstain) that available evidence does not support Deramiocel’s effectiveness for cardiomyopathy in Duchenne muscular dystrophy. The vote is non-binding and focused on a narrower indication than Capricor proposed. Capricor targets an Aug. 22, 2026 PDUFA action date.

finanznachrichten.de4 min
JUL 30
$CAPRHighAI 9/10

Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy - Capricor Therapeutics

Capricor Therapeutics’ Deramiocel for Duchenne muscular dystrophy fell after an FDA advisory panel voted 9-3 that the company did not provide sufficient evidence of effectiveness. FDA staff cited lack of substantial evidence from Study HOPE-3 and no significant differences vs placebo in HOPE-2. Capricor noted The Lancet published HOPE-3 results. Shares were down 52.36% to $3.13.

benzinga.com4 min
JUL 30
$CAPRMed

Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more

An FDA advisory panel voted 9-3 against effectiveness data for Capricor Therapeutics’ Duchenne muscular dystrophy treatment, according to STAT. The panel focused on whether it could treat Duchenne-related cardiomyopathy. The FDA previously declined approval and requested more data, and during the meeting criticized changes to the study’s statistical analysis plan.

statnews.com2 min
JUL 30
$MSFTMed

Microsoft rally offsets Fed jitters; Quanta, Huntington Ingalls gain By Investing.com

U.S. stock index futures rose as Microsoft rallied after a fiscal Q4 2026 earnings beat, with revenue of $90.01B (+18% YoY) and non-GAAP EPS of $4.74. Quanta Services and Huntington Ingalls also gained on better-than-expected results and contract updates. Meta fell after earnings; other movers included Check Point, Capricor, Align, Hyatt, Sirius XM, Trinity, and ImmunityBio.

investing.com5 min